ENDRA Life Sciences (NASDAQ:NDRA) Stock Falls 7.1% – Here’s What Happened

Posted by Francis Steltz on Oct 18th, 2026

ENDRA Life Sciences Inc. (NASDAQ:NDRA – Get Free Report) shares traded down 7.1% during trading on Friday. The company traded as low as $4.74 and last traded at $4.74. 14,349 shares traded hands during trading, a decline of 42% from the average daily volume of 24,664 shares. The stock had previously closed at $5.10.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $25.00.

Get Our Latest Report on NDRA

ENDRA Life Sciences Price Performance

The firm’s fifty day moving average price is $5.41 and its 200-day moving average price is $5.16. The firm has a market capitalization of $7.11 million, a P/E ratio of -0.74 and a beta of -0.09.

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.21. Analysts expect that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current year.

Hedge Funds Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI acquired a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned 2.24% of ENDRA Life Sciences as of its most recent SEC filing. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

(Get Free Report)

ENDRA Life Sciences Corp. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic imaging systems. The company’s primary technology is Thermo-Acoustic Enhanced UltraSound (TAEUS), a platform designed to expand the capabilities of conventional ultrasound by using radiofrequency energy and ultrasound imaging to characterize tissue properties.

ENDRA is initially focused on applying TAEUS to the assessment of liver fat, including fatty liver disease. Its system is intended to provide quantitative information about hepatic steatosis and potentially other tissue characteristics without requiring an invasive biopsy or the use of more costly imaging modalities.